Levothyroxine
Ermeza, Euthyrox, Levo-t, Levolet, Levothyroxine, Levoxyl, Synthroid, Thyquidity, Thyro-tabs, Tirosint, Tirosint-sol, Unithroid (levothyroxine) is a small molecule pharmaceutical. Levothyroxine was first approved as Unithroid on 2000-08-21. It is used to treat autoimmune thyroiditis, goiter, myxedema, thyroid neoplasms, and thyrotoxicosis in the USA. The pharmaceutical is active against thyroid hormone receptor beta and thyroid hormone receptor alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ermeza, Euthyrox, Levo-t, Levolet, Levothyroxine, Levoxyl, Synthroid, Thyquidity, Thyro-tabs, Tirosint, Tirosint-sol, Unithroid (discontinued: Euthyrox, Levothyroxine, Levoxyl)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levothyroxine sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNTHROID | AbbVie | N-021402 RX | 2002-07-24 | 12 products, RLD |
| THYRO-TABS | Alvogen | N-021116 RX | 2002-10-24 | 12 products, RLD |
| THYQUIDITY | Azurity | N-214047 RX | 2020-11-30 | 1 products, RLD, RS |
| LEVO-T | Cediprof | N-021342 RX | 2002-03-01 | 12 products |
| LEVOTHYROXINE SODIUM | Fresenius Kabi | N-202231 RX | 2011-06-24 | 3 products, RLD, RS |
| LEVOTHYROXINE SODIUM | Fresenius Kabi | N-210632 RX | 2019-04-11 | 3 products, RLD, RS |
| LEVOLET | Genus Lifesciences | N-021137 RX | 2003-06-06 | 12 products |
| LEVOTHYROXINE SODIUM | Hikma Pharmaceuticals | N-214253 RX | 2021-05-17 | 1 products, RLD, RS |
| TIROSINT | IBSA Group | N-021924 RX | 2006-10-13 | 15 products, RLD |
| TIROSINT-SOL | IBSA Group | N-206977 RX | 2016-12-15 | 15 products, RLD, RS |
Show 4 marketed
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adthyza | unapproved drug other | 2023-02-23 |
| adthyza thyroid | unapproved drug other | 2025-02-20 |
| ermeza | New Drug Application | 2022-04-15 |
| euthyrox | New Drug Application | 2024-10-24 |
| levo-t | New Drug Application | 2024-07-31 |
| levothroid | New Drug Application | 2012-03-02 |
| levothyroxine | NDA authorized generic | 2014-09-24 |
| levothyroxine sodium | ANDA | 2025-03-20 |
| levoxyl | New Drug Application | 2020-12-15 |
| np thyroid | unapproved drug other | 2021-05-11 |
Show 13 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Levothyroxine Sodium, Tirosint-Sol, Ibsa | |||
| 11241382 | 2039-09-17 | U-3757, U-3758 | |
| 10537538 | 2037-02-28 | DP | |
| 11096913 | 2037-02-28 | DP | |
| Levothyroxine Sodium, Levolet, Genus Lifesciences | |||
| 10231931 | 2038-03-23 | DP | |
| 10406108 | 2038-03-23 | DP | |
| Levothyroxine Sodium, Levothyroxine Sodium, Fresenius Kabi Usa | |||
| 9782376 | 2036-12-01 | DP | |
| 10398669 | 2036-12-01 | DP | |
| 11135190 | 2036-12-01 | DP | |
| 9006289 | 2032-10-03 | DP | |
| 9168238 | 2032-08-29 | DP | |
| 9168239 | 2032-08-29 | DP | |
| Levothyroxine Sodium, Levothyroxine Sodium, Hikma | |||
| 11154498 | 2036-07-20 | DP | |
| Levothyroxine Sodium, Ermeza, Mylan | |||
| 9345772 | 2035-02-27 | DP | |
| Levothyroxine Sodium, Thyquidity, Azurity | |||
| 9050307 | 2031-08-06 | DP | |
| Levothyroxine Sodium, Tirosint, Ibsa | |||
| 7691411 | 2024-03-14 | DP | |
| 7723390 | 2024-03-14 | DP | |
HCPCS
No data
Clinical
Clinical Trials
260 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | 5 | 16 | 12 | 32 | 60 | 118 |
| Thyroid diseases | D013959 | — | E00-E07 | 2 | 10 | 4 | 8 | 33 | 55 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | 6 | 3 | 2 | 15 | 27 |
| Healthy volunteers/patients | — | — | — | 13 | 1 | — | 2 | 1 | 16 |
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | 1 | 3 | 3 | 3 | 9 |
| Congenital hypothyroidism | D003409 | — | E00.1 | — | — | — | 2 | 7 | 9 |
| Syndrome | D013577 | — | — | — | — | 1 | 1 | 4 | 6 |
| Recurrence | D012008 | — | — | 1 | 1 | 1 | 2 | 1 | 6 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 1 | — | 1 | 1 | 5 |
| Goiter | D006042 | EFO_0004283 | E04.9 | — | 1 | — | 3 | 1 | 5 |
Show 47 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | 1 | 1 | — | 10 | 12 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | 4 | 5 |
| Dyslipidemias | D050171 | — | — | — | — | 2 | — | 2 | 4 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 2 | — | 2 | 4 |
| Neoplasms | D009369 | — | C80 | — | 1 | 1 | — | 2 | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | 2 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | 2 | 3 |
| Thyrotoxicosis | D013971 | — | E05 | — | 1 | 1 | — | 1 | 3 |
| Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | 1 | — | 1 | — | 1 | 3 |
| Habitual abortion | D000026 | EFO_1000954 | N96 | 1 | — | 1 | — | 1 | 3 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroiditis | D013966 | — | E06 | — | 1 | — | — | 10 | 11 |
| Autoimmune thyroiditis | D013967 | EFO_0006812 | E06.3 | — | 1 | — | — | 8 | 9 |
| Infertility | D007246 | EFO_0000545 | — | — | 2 | — | — | 3 | 5 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | — | — | 3 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | 2 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 1 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 1 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Alveolar soft part sarcoma | D018234 | — | — | — | 1 | — | — | — | 1 |
| Environmental biomarkers | D000074062 | — | — | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperthyroidism | D006980 | — | E05.9 | 1 | — | — | — | 5 | 6 |
| Melanosis | D008548 | EFO_0003963 | L81.1 | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
| Iron-deficiency anemia | D018798 | — | D50 | 1 | — | — | — | — | 1 |
| Deficiency diseases | D003677 | EFO_1001067 | E63 | 1 | — | — | — | — | 1 |
| Iron deficiencies | D000090463 | — | E61.1 | 1 | — | — | — | — | 1 |
| Heart transplantation | D016027 | EFO_0010673 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | — | — | 4 | 4 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 4 | 4 |
| Carcinoma | D002277 | — | C80.0 | — | — | — | — | 3 | 3 |
| Hyperprolactinemia | D006966 | — | E22.1 | — | — | — | — | 2 | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | — | 2 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 2 | 2 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 2 | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Keratoconus | D007640 | EFO_0004223 | H18.6 | — | — | — | — | 2 | 2 |
| Hormone replacement therapy | D020249 | EFO_0003961 | Z79.890 | — | — | — | — | 2 | 2 |
Show 66 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Levothyroxine |
| INN | levothyroxine sodium |
| Description | L-thyroxine is the L-enantiomer of thyroxine. It has a role as a thyroid hormone, an antithyroid drug, a human metabolite and a mouse metabolite. It is a thyroxine, an iodophenol, a 2-halophenol, a L-phenylalanine derivative and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-thyroxine(1-). It is an enantiomer of a D-thyroxine. It is a tautomer of a L-thyroxine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 51-48-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1624 |
| ChEBI ID | 18332 |
| PubChem CID | 5819 |
| DrugBank | DB00451 |
| UNII ID | 054I36CPMN (ChemIDplus, GSRS) |
Target
Agency Approved
THRA
THRA
Organism
Homo sapiens
Gene name
THRA
Gene synonyms
EAR7, ERBA1, NR1A1, THRA1, THRA2
NCBI Gene ID
Protein name
thyroid hormone receptor alpha
Protein synonyms
c-erbA protooncogene, c-erbA-1, c-erbA-alpha, EAR-7, ERBA-related 7, Nuclear receptor subfamily 1 group A member 1, thyroid hormone receptor alpha 1, thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian), triiodothyronine receptor, V-erbA-related protein 7
Uniprot ID
Mouse ortholog
Thra (21833)
thyroid hormone receptor alpha (Q99146)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Levothyroxine – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Synthroid – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Levothyroxine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,308 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adthyza, Adthyza thyroid, Ermeza, Euthyrox, Levo-t, Levothyroxine sodium, Levoxyl, Np thyroid 60, Np thyroid 90, Sertraline hydrochloride, Synthroid, Thyquidity, Tirosint, Tirosint tirosint, Unithroid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
67,195 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use